In a groundbreaking moment for cancer treatment, Moderna and Merck & Co. have announced stellar Phase 3 trial results for their personalized mRNA cancer vaccine, intismeran autogene (mRNA-4157/V940), combined with Keytruda. The combination significantly reduced the risk of recurrence and spread of high-risk melanoma after surgery, marking the first successful late-stage trial for an mRNA-based cancer therapy. The news, which broke late on August 13, has sent ripples through the biopharmaceutical world, signaling a potential paradigm shift in how we fight cancer.